The FASEB Journal, Vol 7, 951-956, Copyright © 1993 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect

K Bhatia, W Goldschmidts, M Gutierrez, G Gaidano, R Dalla-Favera and I Magrath
Lymphoma Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Activating mutations within the p53 gene cause stabilization and therefore increased steady-state levels of the p53 protein; some, but not all, also result in the generation of an epitope recognized by the antibody pAB240. We have shown here that in 70% of Burkitt lymphoma cell lines, but not in normal EBV transformed B cell lines, p53 protein is readily detectable by Western blot analysis using either an antibody directed against the 240 epitope or an antibody against wild-type p53. Genomic analysis of these BL cell lines demonstrated the presence of mutations within the p53 gene in all cell lines with detectable p53 protein. We have also shown that in the cell lines ST486, Raji, and TE 110, which are heterozygous for a neutral sequence codon polymorphism (Arg/Pro) that causes altered migration of an otherwise normal protein and also contain a heterozygous mutation, only the protein derived from the mutated allele is stabilized. Thus the dominant effect of the mutations present in these cell lines apparently does not result from sequestering of the normal protein by the abnormal protein, and therefore presumably is a consequence of a gain-of-function resulting from the mutation. Although all cell lines with stabilized p53 also contained p53 mutations, three lymphoid tumors (two cell lines and one fresh B-CLL) with a heterozygous mutation at codon 248 did not express elevated levels of p53. In contrast, p53 was readily detectable in Western blot analysis from cell lines KK124, Namalwa, and CA46, which had homo- or hemizygous mutations at codon 248, and from PP1084, a cell line with a codon 273 mutation and a carboxyl-terminal truncation in the other allele. These results suggest that mutations at codon 248, unlike those in cell lines ST486 and TE110, are stabilizing only in the absence of the wild-type p53. Heterozygous mutations at codons 248 have been described in the germline of individuals belonging to cancer-prone families described by Li and Fraumeni (see ref 18), but tumors detected in such individuals are homozygous, i.e., contain only mutated p53. This is consistent with the possibility that such mutations exert a pathogenetic effect only in the absence of the wild-type protein, and are coupled to our findings that stabilization of p53 is a necessary component of the oncogenic pathways relevant to p53. However, whereas some mutations are stabilizing in the presence of the normal p53 protein, others are stabilizing only in the homozygous state.

This article has been cited by other articles:

				A. I. Robles, M. H. Wright, B. Gandhi, S. S. Feis, C. L. Hanigan, A. Wiestner, and L. Varticovski Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines. Clin. Cancer Res., November 1, 2006; 12(21): 6547 - 6556. [Abstract] [Full Text] [PDF]

				M. V. BLAGOSKLONNY p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect FASEB J, October 1, 2000; 14(13): 1901 - 1907. [Abstract] [Full Text]

				M. Kikukawa, N. Aoki, Y. Sakamoto, and M. Mori Study of p53 in Elderly Patients with Myelodysplastic Syndromes by Immunohistochemistry and DNA Analysis Am. J. Pathol., September 1, 1999; 155(3): 717 - 721. [Abstract] [Full Text] [PDF]

				L. Guedez, L. Courtemanch, and M. Stetler-Stevenson Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells Blood, August 15, 1998; 92(4): 1342 - 1349. [Abstract] [Full Text] [PDF]

				Y.-j. Lee and E. Shacter Bcl-2 Does Not Protect Burkitt's Lymphoma Cells From Oxidant-Induced Cell Death Blood, June 15, 1997; 89(12): 4480 - 4492. [Abstract] [Full Text] [PDF]